Cyclacel Pharmaceuticals ... (CYCCP)
| Bid | 3.21 |
| Market Cap | 46.28M |
| Revenue (ttm) | 43K |
| Net Income (ttm) | -9.26M |
| EPS (ttm) | -2.047 |
| PE Ratio (ttm) | -2.06 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 5.34 |
| Volume | 150 |
| Avg. Volume (20D) | 7,244 |
| Open | 4.21 |
| Previous Close | 4.20 |
| Day's Range | 4.21 - 4.21 |
| 52-Week Range | 3.29 - 18.35 |
| Beta | 0.15 |
About CYCCP
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...
8 months ago · seekingalpha.com
Cyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call TranscriptCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Pa...
11 months ago · seekingalpha.com
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call TranscriptCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q1 2024 Earnings Call Transcript May 14, 2024 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - President and CEO Brian Schwartz - CMO Paul ...
2 years ago · seekingalpha.com
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Call TranscriptCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Irina Koffler - Investor Relations Spiro Rombotis - President and Chief Exe...
2 years ago · seekingalpha.com
Cyclacel Pharmaceuticals, Inc. (CYCC) Q3 2022 Earnings Call TranscriptCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Irina Koffler - LifeSci Advisors Spiro Rombotis - President & Chief Exec...
